|
CBWD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.71050001624474E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.80280000319877E-08 |
| Normal-vs-Stage2 |
5.56389999999407E-05 |
| Normal-vs-Stage3 |
1.03210000546028E-08 |
| Normal-vs-Stage4 |
8.51390069556146E-11 |
| Stage1-vs-Stage2 |
6.547400E-01 |
| Stage1-vs-Stage3 |
4.522000E-01 |
| Stage1-vs-Stage4 |
5.295200E-03 |
| Stage2-vs-Stage3 |
3.985400E-01 |
| Stage2-vs-Stage4 |
4.626100E-02 |
| Stage3-vs-Stage4 |
6.564100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.0723999950032E-08 |
| Normal-vs-AfricanAmerican |
6.45769999999546E-05 |
| Normal-vs-Asian |
7.47090167507736E-11 |
| Caucasian-vs-AfricanAmerican |
6.318400E-01 |
| Caucasian-vs-Asian |
1.798840E-03 |
| AfricanAmerican-vs-Asian |
3.022200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.22200002631246E-09 |
| Normal-vs-Female |
6.52970000292186E-09 |
| Male-vs-Female |
7.340600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.96319999648631E-08 |
| Normal-vs-Age(41-60Yrs) |
9.30080001904088E-09 |
| Normal-vs-Age(61-80Yrs) |
4.25870000375639E-08 |
| Normal-vs-Age(81-100Yrs) |
3.241600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.649000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.094000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.594200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.059600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.654000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.148600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.92219995055166E-09 |
| Classical-VS-Follicular |
5.635800E-01 |
| Classical-VS-Other |
6.112200E-01 |
| Classical-VS-Normal |
3.3038999980306E-08 |
| Tall-VS-Follicular |
4.83549999996669E-06 |
| Tall-VS-Other |
2.257800E-01 |
| Tall-VS-Normal |
2.15227835553833E-12 |
| Follicular-VS-Other |
5.234800E-01 |
| Follicular-VS-Normal |
8.30069999957495E-07 |
| Other-VS-Normal |
7.277700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.04350000546583E-08 |
| Normal-vs-N1 |
9.68759999997459E-07 |
| N0-vs-N1 |
4.663000E-01 |
|
|
